-18. Dez. 20204 Min. LesezeitNeuron23 Closes $113.5 Million Series A and B Financing led by Westlake Village BioPartners, KleinDecember 16, 2020 Biotechnology company launches to accelerate development of precision medicines for genetically defined neurological...
-3. Sept. 20194 Min. LesezeitCase Study Origenis GmbH: With Small Molecules against Neurodegenerative DiseasesSeptember 03, 2019 Mithilfe ihrer KI-basierten Small Molecules Technologie schafften es Michael Almstetter und seine zwei Mitstreiter...
-4. Juni 20192 Min. LesezeitOrigenis GmbH Announces Research Collaboration with U.S. Cancer CenterJune 04, 2019 Origenis AI Discovery Platform to Identify and Optimize Small Molecule Preclinical Development Candidates for Glioblastoma...